- ICH GCP
- Registro delle prove cliniche dell'UE
Ultime prove
EudraCT Number: 2008-004583-40 | Sponsor Protocol Number: 101010 | Start Date: | |||||||||||
Sponsor Name: Universitaetsklinikum Muenster | |||||||||||||
Full Title: A randomized, multi-center phase II trial to assess the efficay of 5-azacytidine added to standard primery therapy in elderly patients with newly diagnosed AML. | |||||||||||||
Medical condition: The disease under investigation is newly diagnosed Acute Myeloid Leucemia (AML) in elderly patients. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002936-55 | Sponsor Protocol Number: MSC-EB_2020 | Start Date: | ||||||
Sponsor Name: Masarykova univerzita | ||||||||
Full Title: Safety and Efficacy of Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells in Patients with Epidermolysis Bullosa: Clinical Trial Phase I/II | ||||||||
Medical condition: Epidermolysis bullosa congenita | ||||||||
|
||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||
Trial protocol: CZ (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002482-17 | Sponsor Protocol Number: TAK-935-3003 | Start Date: | ||||||||||||||||
Sponsor Name: Takeda Development Center Americas, Inc | ||||||||||||||||||
Full Title: A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or ... | ||||||||||||||||||
Medical condition: Dravet Syndrome (DS) Lennox-Gastaut Syndrome (LGS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Ongoing) ES (Ongoing) NL (Ongoing) HU (Ongoing) FR (Ongoing) GR (Ongoing) IT (Ongoing) LV (Ongoing) PL (Ongoing) Outside EU/EEA | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002328-34 | Sponsor Protocol Number: KB056 | Start Date: | |||||||||||
Sponsor Name: KEDRION S.P.A | |||||||||||||
Full Title: Efficacy and safety evaluation of Kedrion Fibrin Sealant as an adjuvant for the control of hemostasis in pediatric patients undergoing abdominal or orthopedic surgery. Multicenter, randomized, cont... | |||||||||||||
Medical condition: Paediatric patients undergoing abdominal or orthopedic surgery | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003019-39 | Sponsor Protocol Number: | Start Date: | |||||||||||
Sponsor Name: | |||||||||||||
Full Title: Efficacy & Safety of Nasal Influenza Immunisation in Children - The SNIFFLE-3 study | |||||||||||||
Medical condition: Children aged 2-18 years (inclusive), some of whom will have asthma and/or food allergies. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000976-40 | Sponsor Protocol Number: ION373-CS1 | Start Date: | |||||||||||
Sponsor Name: Ionis Pharmaceuticals, Inc | |||||||||||||
Full Title: A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexand... | |||||||||||||
Medical condition: Alexander Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017477-38 | Sponsor Protocol Number: MEK112110 | Start Date: | |||||||||||
Sponsor Name: GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: An Open-Label, Dose-Escalation, Phase IB/ II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination with Oral Evero... | |||||||||||||
Medical condition: Solid Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-009320-36 | Sponsor Protocol Number: 28431754DIA3009 | Start Date: | |||||||||||
Sponsor Name: Janssen Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ 28431754 100 mg and JNJ-28431754 300 mg Compared Wit... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) DE (Completed) FI (Completed) SK (Completed) DK (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015125-36 | Sponsor Protocol Number: NCT00934687 | Start Date: | ||||||
Sponsor Name: Medical School Hannover. Department of Psychiatry, Social Psychiatry and Psychotherapy | ||||||||
Full Title: Clostridium botulinum Typ A Neurotoxinkomplex zur adjuvanten Behandlung von depressiven Störungen – Eine randomisierte, kontrollierte Pilotstudie | ||||||||
Medical condition: Botulinum Toxin for the Treatment of Depression | ||||||||
|
||||||||
Population Age: Adults | Gender: Male, Female | |||||||
Trial protocol: DE (Completed) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000846-38 | Sponsor Protocol Number: R076477-BIM-3004 | Start Date: | |||||||||||
Sponsor Name: Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Extended-Release Paliperidone as Maintenance Treatment After an ... | |||||||||||||
Medical condition: Bipolar I disorder, most recent maniac or mixed episode | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |